13G Filing: James E. Flynn and Biocryst Pharmaceuticals Inc (BCRX)

Page 8 of 14

Page 8 of 14 – SEC Filing

CUSIP No. 09058V103 13G Page 8
of 11 Pages
Item 1(a). Name of Issuer:

BioCryst Pharmaceuticals, Inc.

Item 1(b). Address of Issuer’s Principal Executive Offices:

4505 Emperor Blvd., Suite 200

Durham, North Carolina 27703

Item 2(a). Name of Person Filing:

James
E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund,
L.P., Deerfield Special Situations Fund, L.P.

Item 2(b). Address of Principal Business Office, or if None, Residence:

James E. Flynn, Deerfield Mgmt, L.P., Deerfield
Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund,
L.P., 780 Third Avenue, 37th Floor, New York, NY 10017

Item 2(c). Citizenship:

Deerfield
Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield Special Situations Fund, L.P. – Delaware limited
partnerships;

Deerfield International Master
Fund, L.P. – British Virgin Islands limited partnership;

James E. Flynn – United
States citizen

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

09058V103

Item 3.

If This Statement is Filed Pursuant to
Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

(a)

Broker or dealer registered under Section 15 of the
Exchange Act.

(b) Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)

Insurance company as defined in Section 3(a)(19) of
the Exchange Act.

(d)

Investment company registered under Section 8 of the
Investment Company Act.

(e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)

An employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F);

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)

Page 8 of 14